Research ArticleFocus on Women and Children

Hydroxyurea and Zileuton Differentially Modulate Cell Proliferation and Interleukin-2 Secretion by Murine Spleen Cells: Possible Implication on the Immune Function and Risk of Pain Crisis in Patients with Sickle Cell Disease

Solo Kuvibidila, Rajasekharan P. Warrier, Johnson Haynes and Surendra B. Baliga
Ochsner Journal September 2015, 15 (3) 241-247;

REFERENCES

  1. ↵
    1. Heeney MM,
    2. Ware RI.
    (2, 2010) Hydroxyurea for children with sickle cell disease. Hematol Onc Clinics N Am 24(1):199–214, doi: 10.1016/j.hoc.2009.11.002.
    OpenUrlCrossRef
  2. ↵
    1. Booth C,
    2. Inusa B,
    3. Obaro SK.
    (1, 2010) Infection in sickle cell disease: a review. Int J Infect Dis 14(1):e2–e12, pmid:19497774, doi: 10.1016/j.ijid.2009.03.010.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Ahmed SG.
    (2011) The role of infection in the pathogenesis of vaso-occlusive crisis in patients with sickle cell disease. Mediterr J Hematol Infect Dis 3(1):e2011028, pmid:21869914, doi:10.4084/MJHID.2011.028.
    OpenUrlCrossRefPubMed
  4. ↵
    1. van Beers EJ,
    2. van Tuijn CF,
    3. Mac Gillavry MR,
    4. van der Giessen A,
    5. Schnog JJ,
    6. Biemond BJ
    (5, 2008) CURAMA study group: Sickle cell disease-related organ damage occurs irrespective of pain rate: implications for clinical practice. Haematologica 93(5):757–760, pmid:18367483, doi: 10.3324/haematol.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Akinsheye I,
    2. Alsultan A,
    3. Solovieff N,
    4. et al.
    (7 7, 2011) Fetal hemoglobin in sickle cell anemia. Blood 118(1):19–27, pmid:21490337, doi: 10.1182/blood-2011-03-325258.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Raghupathy R,
    2. Manwani D,
    3. Little JA.
    (2010) (2010) Iron overload in sickle cell disease. Adv Hematol, 272940, pmid:20490352, doi:10.1155/2010/272940.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Kennedy BJ.
    (6, 1992) The evolution of hydroxyurea therapy in chronic myelogenous leukemia. Semin Oncol 19((3 Suppl 9)):21–26, pmid:1641653.
    OpenUrlPubMedWeb of Science
  8. ↵
    1. Strouse JJ,
    2. Lanzkron S,
    3. Beach MC,
    4. et al.
    (12, 2008) Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics 122(6):1332–1342, pmid:19047254, doi:10.1542/peds.2008-0441.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Brawley OW,
    2. Cornelius LJ,
    3. Edwards LR,
    4. et al.
    (6 17, 2008) National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment of sickle cell disease. Ann Intern Med 148(12):932–938, pmid:18458271.
    OpenUrlCrossRefPubMedWeb of Science
    1. Platt OS.
    (3 27, 2008) Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med 358(13):1362–1369, pmid:18367739, doi: 10.1056/NEJMct0708272.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Charache S,
    2. Dover GJ,
    3. Moore RD,
    4. et al.
    (5 15, 1992) Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood 79(10):2555–2565, pmid:1375104.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Krakoff IH,
    2. Brown NC,
    3. Reichard P.
    (8, 1968) Inhibition of ribonucleoside diphosphate reductase by hydroxyurea. Cancer Res 28(8):1559–1565, pmid:4876978.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Benito JM,
    2. Lopez M,
    3. Lozano S,
    4. Ballesteros C,
    5. Gonzalez-Lahoz J,
    6. Soriano V.
    (7, 2007) Hydroxyurea exerts an anti-prolifeative effect on T cells but has no direct impact on cellular activation. Clin Exp Immunol 149:171–177, pmid:17511775.
    OpenUrlPubMed
  14. ↵
    1. Weinberg A.
    (7, 2001) In vitro hydroxyurea decreases Th1 cell-mediated immunity. Clin Diagn Lab Immunol 8(4):702–705, pmid:11427414.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Lederman HM,
    2. Connolly MA,
    3. Kalpatthi R,
    4. et al.
    (10 1, 2014) BABY HUG Investigators. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics 134(4):686–695, pmid:25180279, doi: 10.1542/peds.2014-0571.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Sterkers Y,
    2. Preudhomme C,
    3. Laï JL,
    4. et al.
    (1 15, 1998) Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 91(2):616–622, pmid:9427717.
    OpenUrlAbstract/FREE Full Text
    1. Wilson S.
    (12 5, 2000) Acute leukemia in a patient with sickle-cell anemia with hydroxyurea. Ann Intern Med 133(11):925–926, pmid:11103075.
    OpenUrlPubMedWeb of Science
  18. ↵
    1. Berthaut I,
    2. Guignedoux G,
    3. Kisch-Noir F,
    4. et al.
    (7, 2008) Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica 93(7):988–993, pmid:18508803, doi: 10.3324/haematol.11515.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Haynes J Jr.,
    2. Baliga BS,
    3. Obiako B,
    4. Ofori-Acquah S,
    5. Pace B.
    (5 15, 2004) Zileuton induces hemoglobin F synthesis in erythroid progenitors: role of the L-arginine-nitric oxide signaling pathway. Blood 103(10):3945–3950, pmid:14764535.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Liu MC,
    2. Dubé LM,
    3. Lancaster J.
    (11, 1996) Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group. J Allergy Clin Immunol 98((5 Pt 1)):859–871, pmid:8939149.
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    1. Israel E,
    2. Cohn J,
    3. Dubé L,
    4. Drazen JM.
    (3 27, 1996) Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. JAMA 275(12):931–936, pmid:8598621.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Marcinkiewicz J,
    2. Grabowska A,
    3. Bryniarski K,
    4. Chain BM.
    (7, 1997) Enhancement of CD4+ T-cell-dependent interleukin-2 production in vitro by murine alveolar macrophages: the role of leukotriene B4. Immunology 91(3):369–374, pmid:9301525.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Bachmann MF,
    2. Oxenius A.
    (12, 2007) Interleukin 2: from immunostimulation to immunoregulation and back again. EMBO Rep 8(12):1142–1148, pmid:18059313.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Olejniczak K,
    2. Kasprzak A.
    (10, 2008) Biological properties of interleukin 2 and its role in pathogenesis of selected diseases—a review. Med Sci Monit 14(10):RA179–RA189, pmid:18830208.
    OpenUrlPubMed
  25. ↵
    1. Sanarico N,
    2. Ciaramella A,
    3. Sacchi A,
    4. et al.
    (9, 2006) Human monocyte-derived dendritic cells differentiated in the presence of IL-2 produce proinflammatory cytokines and prime Th1 immune response. J Leukoc Biol 80(3):555–562, pmid:16809642.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Platt OS.
    (8, 2000) Sickle cell anemia as an inflammatory disease. J Clin Invest 106(3):337–338, pmid:10930436.
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    1. Chies JA,
    2. Nardi NB.
    (7, 2001) Sickle cell disease: a chronic inflammatory condition. Med Hypotheses 57(1):46–50, pmid:11421623.
    OpenUrlCrossRefPubMedWeb of Science
    1. Rodríguez L,
    2. González C,
    3. Flores L,
    4. Jiménez-Zamudio L,
    5. Graniel J,
    6. Ortiz R.
    (4, 2005) Assessment by flow cytometry of cytokine production in malnourished children. Clin Diagn Lab Immunol 12(4):502–507, pmid:15817757.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. González-Torres C,
    2. González-Martínez H,
    3. Milliar A,
    4. et al.
    (2 19, 2013) Effect of malnutrition on the expression of cytokine involved in Th1 cell differentiation. Nutrients 5(2):579–593, pmid:23429441, doi: 10.3390/nu5020579.
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    1. Ngai P,
    2. McCormick S,
    3. Small C,
    4. et al.
    (5, 2007) Gamma interferon responses of CD4 and CD8 T-cell subsets are quantitatively different and independent of each other during pulmonary Mycobacterium bovis BCG infection. Infect Immun 75(5):2244–2252, pmid:17307945.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Sa Q,
    2. Woodward J,
    3. Suzuki Y.
    (3 1, 2013) IL-2 produced by CD8+ immune T cells can augment their IFN-γ production independently from their proliferation in the secondary response to an intracellular pathogen. J Immunol 190(5):2199–2207, pmid:23359502, doi: 10.4049/jimmunol.1202256.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Sojka DK,
    2. Bruniquel D,
    3. Schwartz RH,
    4. Singh NJ.
    (5 15, 2004) IL-2 secretion by CD4+ T cells in vivo is rapid, transient, and influenced by TCR-specific competition. J Immunol 172(10):6136–6143, pmid:15128800.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords